Therapeutics Company Reports Major Progression In Its Phase 2 Study Battling Cancer

The field of oncology has witnessed numerous advancements over the years, yet metastatic breast cancer continues to pose challenges. However, recent developments reported by BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) offer a glimmer of hope. The clinical-stage biotechnology company, known for its innovative immunotherapies, has announced remarkable progress in its ongoing Phase 2 study of the Bria-IMT™ regimen combined with an immune checkpoint inhibitor. This combination therapy has shown a substantial increase in progression-free survival (PFS) for their top responder patient, revealing promising potential for those battling this aggressive form of cancer. $BriaCell Therapeutics Corp(BCT.CA)$